Abstract
Objective To systematically evaluate the effect and safety of Secukinumab for the treatment of rheumatic arthritis (RA).Methods We searched and selected and assessed the articles about randomized controlled trials (RCTs) of evaluating the efficacy and safety of Secukinumab for patients with RA published up to August 31,2016 from PubMed,Medline,EMBase,Web of Science,the Food and Drug Administration (FDA) Website,Clinical Trials Website,Cochrane Library,CNKI,Wanfang Data and VIP.Meta-analysis of data was performed by the RevMan 5.2 software and Stata 12.0 software.Results Six RCTs involving 903 patients were included.Compared with placebo,Secukinumab was more effective in achieving ACR20 [RR=1.56,95％CI (1.31,1.87),P＜0.000 01],ACR50 [RR =2.11,95％CI (1.51,2.93),P＜0.000 01],ACR70 [RR =2.75,95％ CI (1.39,5.43),P =0.004].Secukinumab significantly reduced DAS28-CRP [WMD=-0.48,95％ CI (-0.67,-0.29),P ＜0.000 01],DAS28-ESR [WMD =-0.43,95％ CI (-0.69,-0.16),P=0.001],HAQ-DI [WMD=-0.16,95％CI (-0.24,-0.08),P=0.000 1].In aspect of safety,the risks of severe adverse events [RR =1.97,95％ CI (1.10,3.52),P =0.02] and gastrointestinal disorder [RR =1.81,95％ CI (1.15,2.86),P =0.01] caused by Secukinumab were higher than those by placebo.Egger testing found that,there was no publication bias in the included articles about RCTs of evaluating the efficacy and safety of Secukinumab for RA patients (P =0.205).Conclusion Secukinumab is safe and effective for the treatment of RA.However,due to the small sample size of studies included,it is necessary to develop higher quality RCTs data with larger sample size to evaluate its effectiveness and safety.关键词
关节炎,类风湿/苏金单抗/Meta分析Key words
Arthritis, rheumatoid/Secukinumab/Meta-analysis分类
医药卫生
